Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity

NCT01375803 | Completed

• 1 other identifier: CFIS-09-001
• Study Type: interventional
• Target: 45
• Locations: 2 countries
• Sites: 2

Brief Summary

This study will critically evaluate the effects of a novel dietary fiber administered to subjects at high risk for developing diabetes to determine if this intervention will improve insulin sensitivity compared to control product administration and, thus, decrease risk for developing diabetes. The hypothesis is that consuming this novel fiber twice a day for 12 weeks will significantly decrease fasting plasma glucose, insulin and glycosylated hemoglobin values in pre-diabetic subjects (i.e. subjects with fasting plasma glucose levels 95-140 mg/dl at screening) compared to consumption of the control product.

Conditions

Insulin Resistance

Keywords

dietary fiber; fiber; insulin sensitivity; insulin resistance; glucose metabolism

Outcome Measures

Primary Outcomes (3)

• Mean changes in fasting and post-glucose administration values for plasma glucose from baseline to end of study

  0, 6, 9, 12 weeks

• Mean changes in fasting and post-glucose administration values for plasma insulin from baseline to end of study

  0, 6, 9, 12 weeks

• Mean changes in blood HbA1c values from baseline to end of study

  0, 12 weeks

Secondary Outcomes (4)

• Mean changes from baseline to end of study in HOMA

  0, 6, 9, 12 weeks

• Percentage change and absolute change from baseline in body weight

  0, 3, 6, 9, 12 weeks

• Mean changes from baseline in waist circumference

  0, 12 weeks

• Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]

  0, 12 weeks

Study Arms (3)

1

EXPERIMENTAL

3g/day

Dietary Supplement: Novel dietary fiber

2

EXPERIMENTAL

6g/day

Dietary Supplement: Novel dietary fiber

Placebo beverage

PLACEBO COMPARATOR

0g/day

Other: Placebo

Interventions

Novel dietary fiber DIETARY_SUPPLEMENT

oral consumption in beverage

1

Placebo OTHER

Oral consumption in beverage

Placebo beverage

Eligibility Criteria

• Age: 30 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female of any racial/ethnic group; able to read, comprehend, and write English at a sufficient level to complete study-related materials
• Age: at least 30 and no more than 70 years at randomization into this trial
• BMI: 25-40 kg/m2 at randomization into this trial
• Fasting blood glucose: 95-140 mg/dl (for those with glucose 95-99mg/dl, must have history of gestational diabetes or first degree relative (parent or sibling) with history of diabetes; for those with glucose 100-125 mg/dl, will be enrolled as the primary target for recruitment; for those with glucose 126-140 mg/dl (asymptomatic diabetes), must not have prior diagnosis of diabetes and must not have prior treatment/pharmacotherapy for diabetes)
• Good general health as evidenced by the medical history
• Blood chemistry and urinalysis results within normal ranges or within an acceptable range determined by the physician on site and/or in consultation with the Medical Monitor
• Available and willing to participate in the study for up to 15 weeks
• Willing to follow a weight-maintaining Lifestyle diet throughout the 12 week trial, maintain physical activity patterns at baseline levels throughout the study period, and not add new exercise routines, dietary supplements, vitamins or other unusual food products
• Willing to consume two 16 oz beverages every day with meals for 12 weeks and able to transport the test article

You may not qualify if:

• Presence of any condition the Investigator believes would interfere with subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk
• Food allergy or sensitivity to any of the ingredients in the study product (e.g. Gluten sensitivity, celiac disease)
• Participation in another clinical trial that might interfere with this trial or exposure to any investigational agent within 30 days prior to first visit
• History of diabetes (subjects with a prior history of gestational diabetes may be enrolled if they had no pharmacologic treatment for diabetes since pregnancy)
• Treatment for diabetes or a related condition (e.g., polycystic ovary syndrome) with metformin, an oral agent, or insulin or other injections used for diabetes management
• Uncontrolled hypertension (i.e., systolic blood pressure \>160 mm Hg, or a diastolic blood pressure \>95 mmHg based on an average of 3 readings sitting)
• Fasting serum triglyceride value \>250 mg/dl (since changes in triglyceride values can affect glucose homeostasis)
• Untreated hypothyroidism with a TSH \> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
• Recent history of weight loss (\>4 kg in the past 3 months) or a significant variation in weight (\>4 kg in the past 3 months, for example, due to a medical condition such as pregnancy, or hormonal therapy)
• Use of medications or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months
• Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor)
• Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception throughout the study period.

Sponsors & Collaborators

• Cargill: lead

Study Sites (2)

Louisville Metabolic and Atherosclerosis Research Center

Louisvile, Kentucky, 40213, United States

Location

KGK Synergize Inc.

London, Ontario, N6A 5R8, Canada

Location

Related Publications (7)

• Weickert MO, Mohlig M, Schofl C, Arafat AM, Otto B, Viehoff H, Koebnick C, Kohl A, Spranger J, Pfeiffer AF. Cereal fiber improves whole-body insulin sensitivity in overweight and obese women. Diabetes Care. 2006 Apr;29(4):775-80. doi: 10.2337/diacare.29.04.06.dc05-2374.

  PMID: 16567814 BACKGROUND

• Lu ZX, Walker KZ, Muir JG, Mascara T, O'Dea K. Arabinoxylan fiber, a byproduct of wheat flour processing, reduces the postprandial glucose response in normoglycemic subjects. Am J Clin Nutr. 2000 May;71(5):1123-8. doi: 10.1093/ajcn/71.5.1123.

  PMID: 10799374 BACKGROUND

• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003 Oct;22(5):331-9. doi: 10.1080/07315724.2003.10719316.

  PMID: 14559925 BACKGROUND

• Behall KM, Scholfield DJ, Hallfrisch J. Comparison of hormone and glucose responses of overweight women to barley and oats. J Am Coll Nutr. 2005 Jun;24(3):182-8. doi: 10.1080/07315724.2005.10719464.

  PMID: 15930484 BACKGROUND

• Jenkins AL, Jenkins DJ, Zdravkovic U, Wursch P, Vuksan V. Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Eur J Clin Nutr. 2002 Jul;56(7):622-8. doi: 10.1038/sj.ejcn.1601367.

  PMID: 12080401 BACKGROUND

• Keenan JM, Goulson M, Shamliyan T, Knutson N, Kolberg L, Curry L. The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. Br J Nutr. 2007 Jun;97(6):1162-8. doi: 10.1017/S0007114507682968. Epub 2007 Apr 20.

  PMID: 17445284 BACKGROUND

• Bays H, Frestedt JL, Bell M, Williams C, Kolberg L, Schmelzer W, Anderson JW. Reduced viscosity Barley beta-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus. Nutr Metab (Lond). 2011 Aug 16;8:58. doi: 10.1186/1743-7075-8-58.

  PMID: 21846371 DERIVED

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Harold E Bays, MD, FACP

  Louisville Metabolic and Atherosclerosis Research Center

  PRINCIPAL INVESTIGATOR

• Dale R Wilson, MD, CCFP(EM), FCFP

  KGK Science Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 16, 2011
• First Posted: June 17, 2011
• Study Start: June 1, 2009
• Primary Completion: August 1, 2010
• Study Completion: August 1, 2010
• Last Updated: June 17, 2011

Record last verified: 2011-06

Locations

US (1); CA (1)